Skip to main content
Premium Trial:

Request an Annual Quote

Inivata Scientific Advisory Board

Inivata has announced formation of a new scientific advisory board, chaired by Edward Kim of the Levine Cancer Institute. Kim currently serves as a distinguished chair for cancer research and chairman of solid tumor oncology and investigational therapeutics at Levine.

Also joining the board are Benjamin Besse, Ramaswamy Govindan, Geoffrey Oxnard, Lee Schwartzberg, and Sandra Swain. Besse is chairman of the thoracic unit at Gustave Roussy Cancer Center in Paris. Govindan is a professor of medicine and a chair of medical oncology at Washington University School of Medicine. Oxnard is a thoracic oncologist at the Dana-Farber Cancer Institute and an assistant professor at Harvard Medical School. Schwartzberg is executive director of the West Cancer Center and chief of the division of hematology/oncology at the University of Tennessee Health Science Center. He is also the president and chief medical officer of Vector Oncology and serves on the board of directors of the National Comprehensive Cancer Network. Swain serves as a professor and associate dean for research and development at the Georgetown University School of Medicine.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.